期刊文献+

棘白霉素B母核在低级醇-丙酮体系中的纯化研究

Purification of Echinocandin B Nucleus in the Mixture of Lower Alkanol and Acetone
下载PDF
导出
摘要 棘白霉素B母核(ECBN)结晶纯化是提取步骤中最为重要的一个步骤,通过实验,摸索出了ECBN的最佳结晶条件,乙醇/丙酮为最优纯化体系,当混合液中乙醇含量为4%~5%,混合液用量为浓缩液的10~14倍体积时,棘白霉素B母核有很好的纯化效果和较高的收率。 Purification of echinocandin B nucleus is a important extraction process. The mixture of ethanol and acetone was the optimum crystallization condition and when the ethanol content was 4%~5%, the mixture consumption was 10~14 times of the concentrate echinocandin B nucleus has good purification effect and high yield.
作者 王晶珂 谢新宇 张炜 王崔岩 冷凤 李敏 Wang jing-ke;Xie xin-yu;Zhang wei;Wang cui-yan;Leng feng;Li min(National Engineering Research Center of Microbial Medicine,Hebei industry Microbial Metabolic Engineering & technology ResearchCenter,New Drugs Research & Development of North China Pharmaceutical Grop Corporation, Shijiazhuang 050015)
出处 《国外医药(抗生素分册)》 CAS 2019年第3期291-294,共4页 World Notes on Antibiotics
基金 国家“重大新药创制”科技专项2018ZX09301002
关键词 棘白霉素B 母核 纯化 阿尼芬净 Echinocandin B nucleus Purification Anidulafungin
  • 相关文献

参考文献2

二级参考文献31

  • 1Ostrosky-Zeicher L. New approaches to the risk of candida in the intensive care unit[J]. Curr Opin infect Dis, 2003,16(6) :533 -537.
  • 2Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis[J]. Clin Infect Dis ,2003,37 (Suppl 3): S157 - S187.
  • 3Debono M, Turner WW, La Grandeur L, et al. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipephilic and geometric parameters of polyarylated acyl analogs of ECB [J]. J Med Chem,1995,38(17) :3271 - 3281.
  • 4Debono M,Abbptt BJ,Turner JR, et al. Synthesis and evaluation of LY-121019, a member of a series of Semisynthetic analogs of the antifungal lipopeptide echinocandin B[J]. Ann NY Acad Sci, 1988,544: 152- 167.
  • 5Pfaller MA, Hollis R, Goldstein BP, et al. In vitro activity of anidulafungin (ANID) and other agents against 526 Esophageal candidiasis isolates [ A ]. 43rd interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology [ C ]. Chicago: Illinois, 2003. Abstract M-1226.
  • 6Murdoch D, Plosker GL.Anidulafungin[J]. Drug, 2004,64(19):2249 - 2258.
  • 7Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS nethods for 12,052 fungal isolates: review of the literature [ J ]. Rev Iberoam Mico, 2003,20(4): 121 - 136.
  • 8Petraitis V, Petraitiene R, Groll AH, et al. Dosage-dependent antifungal efficacy of V-echinocandin ( LY303366 ) against experimental fluconazole-resistant oropharyngeal and Esophageal candidiasis [ J ]. Antimicrob Agents Chemother , 2001, 45 (2): 471 -479.
  • 9Verweij PE, Oakley KL, Morrissey J, et al. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergil losis[J]. Antimicrob Agents Chemother, 1998, 42(4): 873 - 878.
  • 10Denning DW. Echinocandin antifungal drugs [ J ]. Lancet, 2003,362(10) :1142- 1151.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部